Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sean Bohen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 150
- Beta
- 1.99
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 5.28
Financials
Net Income
$-63.20MEBITDA
$-62.98MFree Cash Flow
$-45.90MEPS (diluted)
$-0.61Shares Outstanding (diluted)
104.45M+640.9%Operating Expenses
$67.18MCash & Debt
$461.07MReturn of Capital
$4.65MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-162.45M | $-1.87 |
| 2024 | $0.00 | $-129.47M | $-2.20 |
| 2023 | $0.00 | $-96.66M | $-2.14 |
| 2022 | $0.00 | $-104.79M | $-2.62 |
| 2021 | $0.00 | $-71.10M | $-1.79 |
| 2020 | $0.00 | $-22.12M | $-0.58 |
| 2019 | $0.00 | $-4.32M | $-0.11 |
| 2018 | $0.00 | $-2.20M | $-0.16 |
Valuation
OLMAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·25d ago·Positive
Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Olema Pharmaceuticals, Inc. (OLMA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
View source ↗ - Newsbenzinga.com·55d ago·Neutral
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first quarter of 2027.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.60 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$-0.61 vs $-0.55miss
- Tue, May 12$-0.52 vs $-0.52beat
- Mon, Mar 16$-0.50 vs $-0.51beat
- Mon, Nov 10$-0.49 vs $-0.44miss
- Mon, Aug 11$-0.51 vs $-0.43miss
- Tue, May 13$-0.36 vs $-0.49beat
Estimates and results for OLMA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OLMA officers and directors.
- Bought
- —
- Sold
- $24.9m
0 trades
29 trades
- Harmon Cyrussold
- Harmon Cyrussold
- Mitchell Shawntesold
- Mitchell Shawntesold
- Mitchell Shawntesold
- Harmon Cyrussold
- Kovacs Shane William Charlessold
- Harmon Cyrussold
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OLMA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.